Assessing chemotherapy

Ultrasound presents an alternative to radiation

Injecting toxic chemicals into the body to kill cancer cells is a physically and mentally brutal experience for patients. The treatment cost is equally brutal for healthcare systems. Yet, often after six months of difficult treatment, patients may hear that the chemotherapy did not stop or kill the cancer. There is now a way to find out, in just 30 days and at a cost of just €183, whether the treatment is doing any good. A further plus: the exam does not expose a patient to radiation.

Report: John Brosky

Hepatic metastasis before (upper images) and after 42 days of antiangiogenic...
Hepatic metastasis before (upper images) and after 42 days of antiangiogenic treatment (lower images). B-mode and contrast-enhanced-ultrasound image with time-intensity-curve analysis.
Source: Toshiba Medical
Nathalie Lassau, M.D.
Nathalie Lassau, M.D.
Source: ECR Today 2014 - Saturday

This three-minute exam, with an injection of a contrast agent, microscopic air bubbles illuminate blood circulation for ultrasound probes and can expose tumours. Proven effective through clinical studies and recommended by WFUMB and EFSUMB – the World and European and federations for ultrasound in medicine and biology – the dynamic contrast-enhanced ultrasound exam (DCE-US) can determine whether chemotherapy is working and help the oncologist to decide whether treatment should be stopped, continued or even increased.

Nathalie Lassau MD, from the Gustave Roussy Institute for cancer research in Paris, has been working with clinicians and ultrasound companies for 10 years to carefully advance this disruptive procedure through demanding requirements for clinical validation. Having won approval and recommendations for the technique in Europe, she says her goal is now to win approval in the USA, where the contrast agent has recently been approved. ‘We can provide the oncologist with the results of the assessment in real-time – no one is able to do this with either a CT or an MRI Scanner.’

Key to her work has been a collaboration with Toshiba Medical systems that was the only ultrasound system manufacturer to provide the raw linear data essential to create the calculations and analysis of tumour response to chemotherapy. Today, all major ultrasound manufacturers have opened their systems to enable this breakthrough technique.

It has also attracted the interest of pharmaceutical companies, as keen as patients to know if their therapies are effective. ‘Cancer has become a chronic disease,’ said Lassau. ‘And today there are many drugs to treat carcinoma. It’s possible that a patient will start with one drug, then be switched to another drug, and so on. In my institution, a single patient may be tested across six different drugs.

‘If a patient’s doctor is following the current international standards, then the doctor will perform a Response Evaluation Criteria In Solid Tumours (RECIST) evaluation, which uses CT. This means the patient is being exposed to radiation to evaluate the effectiveness of the chemotherapy,’ she pointed out. ‘There is a strong association, supported by articles in leading medical journals, where they show there is a risk for inducing a secondary cancer through the radiation of patients with CT.’

Performing a CT perfusion exam to see whether chemotherapy is working means exposing the patient to 20 millsieverts (mSv) of radiation for each exam. ‘I don’t know about other countries, but I know that, in France, 20 mSv is the maximum dose allowable for one patient during a full year. With cancer patients there is a risk of scanning them every two or three months,’ Lassau explains.

Some people might say that if a patient is dying from cancer, then the risk of creating a second cancer with radiation is not as important. ‘This is a cynical view,’ according to Lassau. ‘There has been significant progress made in chemotherapy for many types of cancer and the life expectancy of patients is greatly increased.’

Patients are especially concerned about the risks of radiation exposure, and she said patient advocacy groups are helping to increase the awareness that there is now an alternative way of learning if chemotherapy is working.

Lassau continues to advance the DCE-US, currently leading a new multi-centre clinical trial to demonstrate the technique’s effectiveness and reproducibility of results. The next step, she says, is to develop the system using ultrasound imaging in 3-D. ‘All ultrasound companies now offer 3-D probes and we want to show a full acquisition to be sure we are studying the total tumour.’

07.03.2015

Read all latest stories

Related articles

Photo

News • CT, MRI, X-ray, AI, PACS, endoscopy, ultrasound

Fujifilm Healthcare acquires Hitachi Diagnostic Imaging, presents new portfolio

At a virtual European event, Fujifilm Healthcare Europe presented a complete and integrated portfolio of diagnostic products and services, including CT, MRI, X-ray, AI, PACS, endoscopy and ultrasound…

Photo

Article • Gender equality

Have women's career chances improved in radiology?

The role of women in radiology and the challenges they face were again the focus of a session — Women in Radiology: How to maximise their potential — at this year's ECR, when female and male…

Photo

News • Imaging AI

Photon-counting CT improves myeloma bone disease detection

New CT technology paired with artificial intelligence-based noise reduction offers superior detection of bone disease associated with multiple myeloma at lower radiation doses than conventional CT.

Related products

Canon – Alphenix 4D CT

Multi-Modality Suites

Canon – Alphenix 4D CT

Canon Medical Systems Europe B.V.
Canon - Aquilion Exceed LB

Oncology CT

Canon - Aquilion Exceed LB

Canon Medical Systems Europe B.V.
Canon – Aquilion LB

Oncology CT

Canon – Aquilion LB

Canon Medical Systems Europe B.V.
MinFound – ScintCare CT128

Volume CT

MinFound – ScintCare CT128

MinFound Medical Systems Co., Ltd
Nexus/Chili – Diagnost

Reading

Nexus/Chili – Diagnost

Nexus/Chili GmbH
OR Technology - dicomPACS

RIS/PACS

OR Technology - dicomPACS

OR Technology (Oehm und Rehbein GmbH)
Subscribe to Newsletter